UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2018
AngioDynamics, Inc.
(Exact Name of Registrant as Specified in Charter)
| |
Delaware
|
000-50761
|
11-3146460
|
| |
|
|
|
| |
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
14 Plaza Drive Latham, New York 12110
|
|
| |
|
|
(Address of Principal Executive Offices) (Zip Code)
|
|
| |
|
|
(518) 795-1400
|
|
| |
|
|
(Registrant’s telephone number, including area code)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 – Other Events.
On January 24, 2018, AngioDynamics, Inc. (the “Company”) issued a press release announcing that the United States Food and Drug Administration has granted the Expedited Access Pathway designation to the Company’s NanoKnife® System and proposed indication for use for the treatment of Stage III pancreatic cancer. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01 – Financial Statements and Exhibits
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
| |
|
|
|
99.1
|
|
Press Release dated January 24, 2018.
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ANGIODYNAMICS, INC. |
|
| |
(Registrant) |
|
| |
|
|
|
| |
|
|
|
|
Date: January 24, 2018
|
By:
|
/s/ Stephen A. Trowbridge |
|
| |
|
Stephen A. Trowbridge |
|
| |
|
Senior Vice President and General Counsel |
|
| |
|
|
|